Developer docs
API playgroundTry for free, no card

Search company profiles

Valerion Therapeutics, LLC

Full company profile

uuid00024o8

Namestring
Valerion Therapeutics, LLC
Legal namestring
Valerion Therapeutics, LLC
Websiteurl
valerion.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Valerion Therapeutics, LLC is a privately held biopharmaceutical company founded in 2007 that develops therapies for orphan genetic muscle diseases using a novel antibody-based targeting system. The company's therapeutic platform is built around single-domain antibodies (nanobodies), a specialized modality within antibody-based therapeutics, and the company is positioning itself for next-generation immunotherapy pipelines. Its core R&D capabilities were materially expanded through the September 2024 acquisition of Emglev Therapeutics, a specialist in single-domain antibodies, which was integrated as a wholly owned subsidiary with its brand retained. With only 1-10 employees reported, Valerion operates as a pre-commercial, development-stage entity; no product sales or licensing revenue are disclosed in the input, and the implied business model is future revenue from licensing, out-licensing, or co-development arrangements with larger pharmaceutical partners. A notable data conflict exists between the firmographic profile (headquartered in Medford, United States) and a third-party source describing the entity as France-based; this jurisdictional discrepancy is unresolved in the input and is noted as a data gap. Separately, the valerion.com domain is operated by a consumer electronics brand ("AWOL Valerion") selling 4K RGB triple laser projectors; the input indicates no overlap between that consumer hardware business and Valerion Therapeutics, LLC, and the projector data should not be attributed to the biopharma entity.

Short descriptiontext

Valerion Therapeutics, LLC is a privately held, pre-commercial biopharmaceutical company developing antibody-based therapeutics — including single-domain antibodies (nanobodies) — for orphan genetic muscle diseases, operating with 1-10 employees since 2007.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMedford, United States
HQ citystring
Medford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
4K laser projectors, home theater projectors, RGB triple laser, gaming projectors, streaming projectors
Product category
Home Theater Projectors
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-commercial biopharmaceutical R&D
TypeLicensing Royalties
Description

Valerion Therapeutics is positioned as a developer of antibody-based therapeutics in the nano antibodies space; the source does not disclose specific revenue streams or commercial product sales, indicating pre-commercial/development-stage operations with future potential revenue from licensing, partnerships, or product sales to pharmaceutical buyers.

openpr.com
Cost components5 values
Supply Chain, Technology or R&D, Marketing or Sales, Operations, Personnel
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Valerion Therapeutics, LLC (operating as AWOL Valerion) designs, markets, and sells premium 4K RGB triple laser home theater projectors through its direct-to-consumer e-commerce site at valerion.com. The lineup spans the flagship VisionMaster Max, the gaming-oriented VisionMaster Pro 2 & Pro (Red Dot Award 2025 winner), and the streaming-focused StreamMaster Plus 2 & Plus, complemented by accessory bundles including PureVision Anti-Speckle screens, outdoor and backyard screens, tripod and ceiling mounts, and the Thunderbeat 4.1.2 audio system.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

AWOL Valerion operates a single-product family architecture centered on premium 4K RGB triple laser home theater projectors, organized into three tiers: the flagship VisionMaster Max (highest brightness at 3500 ISO lumens and 50000:1 contrast), the mid-tier VisionMaster Pro 2 & Pro (3000 ISO lumens, gaming-optimized), and the StreamMaster Plus 2 & Plus (streaming-focused). All projectors share a common RGB triple laser light source with 110% Rec.2020 gamut, AI-SoC MT9618 chipset, built-in Google TV with AirPlay 2/Chromecast/Miracast, Dolby Vision/HDR10/IMAX Enhanced/Active 3D, and smart home integration with Google Home, Apple HomeKit, Alexa, and Control4. The portfolio is complemented by accessory bundles including matte white and PureVision Anti-Speckle projector screens, tripod and ceiling mounts, outdoor camping/backyard screens, and the Thunderbeat 4.1.2 audio system.

Product and service5 records
1VisionMaster Max 4K RGB Triple Laser Projector
CategoryHome theater projector
Description

Flagship professional-grade 4K RGB triple laser home theater projector delivering 3500 ISO lumens, 50000:1 viewing contrast, 110% Rec.2020 color gamut, EBL (Enhanced Black Level) algorithm, and support for screens up to 300 inches with IMAX Enhanced, Dolby Vision, HDR10, and Active 3D. Sold direct to consumers at $3,399–$3,999 USD on valerion.com.

2VisionMaster Pro 2 & Pro 4K RGB Triple Laser Projector
CategoryGaming and home theater projector
Description

Mid-tier 4K RGB triple laser projector line targeting gaming and home theater with 3000 ISO lumens, 15000:1 viewing contrast, AI-SoC MT9618 chipset, 4GB RAM / 128GB ROM, 4ms input lag at 1080p@240Hz, ultrawide 21:9 and 32:9 support, plus IMAX Enhanced and Active 3D. Sold direct to consumers starting at $2,099 USD on valerion.com.

3StreamMaster Plus 2 & Plus 4K RGB Triple Laser Projector
CategoryStreaming projector
Description

Streaming-focused 4K RGB triple laser projector with MT9618 processor supporting 4K 120Hz, RGB laser 110% Rec.2020 color gamut, 10,000:1 contrast, built-in Google TV, Dolby Atmos and DTS:X audio, plus IMAX Enhanced and Active 3D. Sold direct to consumers at $1,999 USD on valerion.com.

4PureVision Anti-Speckle Screen
CategoryProjector screen accessory
Description

Anti-speckle projector screen designed to pair with AWOL Valerion RGB laser projectors, available in fixed frame and motorized variants for speckle reduction and improved image clarity.

5Thunderbeat 4.1.2 Speaker
CategoryAudio accessory
Description

4.1.2 channel audio upgrade speaker bundle for AWOL Valerion projectors offering enhanced home theater sound.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Chinese premium projector specialist selling 4K home theater and portable projectors (Horizon, AURA series) at comparable price points. XGIMI is the most direct peer in the premium RGB/LED laser consumer projector category with overlapping customer base and similar DLP-based technology stack.

TypeDirect peer
Description

Premium Chinese projector maker offering RGB laser home theater projectors (N1, N1S series) at similar price tiers. Competes head-to-head with Valerion on RGB triple laser technology, Google TV integration, and premium home cinema positioning.

TypeDirect peer
Description

Established DLP projector brand with strong home theater and gaming projector lines (HT, X, TK series). Targets the same premium home cinema segment with comparable brightness and 4K specifications, and has well-developed retail distribution.

TypeDirect peer
Description

Emerging Chinese projector brand (Mars, S7, K3 series) selling premium 4K laser projectors with Google TV. Directly comparable product line, pricing strategy, and target customer segment.

TypeBroad incumbent
Description

Premium incumbent with the BRAVIA Projector line including the VPL-XW7000ES and VPL-GTZ380. Sony is the dominant high-end home theater projector brand and competes in the same ultra-premium tier above Valerion's flagship.

TypeBroad incumbent
Description

Global consumer electronics incumbent offering CineBeam 4K laser projectors (HU915, HU810) at premium price points. Competes via broader brand reach, retail presence, and integrated webOS smart platform.

TypeBroad incumbent
Description

Hisense's Laser TV / Laser Cinema line (L9H, PX3) is among the highest-volume premium RGB laser TV products globally. As a tier-one TV brand, Hisense competes on price-performance and bundled screen offerings.

TypeBroad incumbent
Description

Established projector incumbent with a full home theater lineup (Pro Cinema, Home Cinema series). While traditionally lamp-based, Epson is moving into laser and competes for the same premium home theater buyer.

TypeEmerging player
Description

Consumer projector brand under Anker, with portable and home models (Cosmos, Capsule series). Targets adjacent but lower price tiers; relevant as a benchmark for go-to-market scale and brand-building in the consumer projector category.

TypeDirect peer
Description

Dedicated projector specialist with a broad home cinema lineup (CinemaX, UHZ series) at competitive premium price points. Comparable product positioning and distribution strategy in the DLP home theater segment.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration11 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Valerion Therapeutics, LLC

Home Theater Projectorsvalerion.com

Valerion Therapeutics, LLC is a privately held, pre-commercial biopharmaceutical company developing antibody-based therapeutics — including single-domain antibodies (nanobodies) — for orphan genetic muscle diseases, operating with 1-10 employees since 2007.

What Valerion Therapeutics, LLC does

Valerion Therapeutics, LLC is a privately held biopharmaceutical company founded in 2007 that develops therapies for orphan genetic muscle diseases using a novel antibody-based targeting system. The company's therapeutic platform is built around single-domain antibodies (nanobodies), a specialized modality within antibody-based therapeutics, and the company is positioning itself for next-generation immunotherapy pipelines. Its core R&D capabilities were materially expanded through the September 2024 acquisition of Emglev Therapeutics, a specialist in single-domain antibodies, which was integrated as a wholly owned subsidiary with its brand retained. With only 1-10 employees reported, Valerion operates as a pre-commercial, development-stage entity; no product sales or licensing revenue are disclosed in the input, and the implied business model is future revenue from licensing, out-licensing, or co-development arrangements with larger pharmaceutical partners. A notable data conflict exists between the firmographic profile (headquartered in Medford, United States) and a third-party source describing the entity as France-based; this jurisdictional discrepancy is unresolved in the input and is noted as a data gap. Separately, the valerion.com domain is operated by a consumer electronics brand ("AWOL Valerion") selling 4K RGB triple laser projectors; the input indicates no overlap between that consumer hardware business and Valerion Therapeutics, LLC, and the projector data should not be attributed to the biopharma entity.

Valerion Therapeutics, LLC firmographics

Firmographics
Name
Valerion Therapeutics, LLC
Legal name
Valerion Therapeutics, LLC
Website
https://valerion.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
Valerion Therapeutics, LLC is a privately held, pre-commercial biopharmaceutical company developing antibody-based therapeutics — including single-domain antibodies (nanobodies) — for orphan genetic muscle diseases, operating with 1-10 employees since 2007.
Ownership category
akta.pro rank

Where Valerion Therapeutics, LLC is headquartered

Location

Headquarters

HQ city
Medford
HQ country
United States
HQ region
North America

Markets served

Valerion Therapeutics, LLC business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Marketing or Sales, Operations, Personnel

Revenue model

  1. Pre-commercial biopharmaceutical R&D: Valerion Therapeutics is positioned as a developer of antibody-based therapeutics in the nano antibodies space; the source does not disclose specific revenue streams or commercial product sales, indicating pre-commercial/development-stage operations with future potential revenue from licensing, partnerships, or product sales to pharmaceutical buyers.

Go-to-market motion1 record

Valerion Therapeutics, LLC product offering

Product offering

Core offering

Valerion Therapeutics, LLC (operating as AWOL Valerion) designs, markets, and sells premium 4K RGB triple laser home theater projectors through its direct-to-consumer e-commerce site at valerion.com. The lineup spans the flagship VisionMaster Max, the gaming-oriented VisionMaster Pro 2 & Pro (Red Dot Award 2025 winner), and the streaming-focused StreamMaster Plus 2 & Plus, complemented by accessory bundles including PureVision Anti-Speckle screens, outdoor and backyard screens, tripod and ceiling mounts, and the Thunderbeat 4.1.2 audio system.

Product overview

AWOL Valerion operates a single-product family architecture centered on premium 4K RGB triple laser home theater projectors, organized into three tiers: the flagship VisionMaster Max (highest brightness at 3500 ISO lumens and 50000:1 contrast), the mid-tier VisionMaster Pro 2 & Pro (3000 ISO lumens, gaming-optimized), and the StreamMaster Plus 2 & Plus (streaming-focused). All projectors share a common RGB triple laser light source with 110% Rec.2020 gamut, AI-SoC MT9618 chipset, built-in Google TV with AirPlay 2/Chromecast/Miracast, Dolby Vision/HDR10/IMAX Enhanced/Active 3D, and smart home integration with Google Home, Apple HomeKit, Alexa, and Control4. The portfolio is complemented by accessory bundles including matte white and PureVision Anti-Speckle projector screens, tripod and ceiling mounts, outdoor camping/backyard screens, and the Thunderbeat 4.1.2 audio system.

Differentiator

Problem solved

Functional benefit

Products and services

  • VisionMaster Max 4K RGB Triple Laser Projector Flagship professional-grade 4K RGB triple laser home theater projector delivering 3500 ISO lumens, 50000:1 viewing contrast, 110% Rec.2020 color gamut, EBL (Enhanced Black Level) algorithm, and support for screens up to 300 inches with IMAX Enhanced, Dolby Vision, HDR10, and Active 3D. Sold direct to consumers at $3,399–$3,999 USD on valerion.com.
  • VisionMaster Pro 2 & Pro 4K RGB Triple Laser Projector Mid-tier 4K RGB triple laser projector line targeting gaming and home theater with 3000 ISO lumens, 15000:1 viewing contrast, AI-SoC MT9618 chipset, 4GB RAM / 128GB ROM, 4ms input lag at 1080p@240Hz, ultrawide 21:9 and 32:9 support, plus IMAX Enhanced and Active 3D. Sold direct to consumers starting at $2,099 USD on valerion.com.
  • StreamMaster Plus 2 & Plus 4K RGB Triple Laser Projector Streaming-focused 4K RGB triple laser projector with MT9618 processor supporting 4K 120Hz, RGB laser 110% Rec.2020 color gamut, 10,000:1 contrast, built-in Google TV, Dolby Atmos and DTS:X audio, plus IMAX Enhanced and Active 3D. Sold direct to consumers at $1,999 USD on valerion.com.
  • PureVision Anti-Speckle Screen Anti-speckle projector screen designed to pair with AWOL Valerion RGB laser projectors, available in fixed frame and motorized variants for speckle reduction and improved image clarity.
  • Thunderbeat 4.1.2 Speaker 4.1.2 channel audio upgrade speaker bundle for AWOL Valerion projectors offering enhanced home theater sound.

Companies that use Valerion Therapeutics, LLC

Customer profile

Ideal customer profiles2 records

Valerion Therapeutics, LLC technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability4 records

Feature1 record

Valerion Therapeutics, LLC partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights3 records

Valerion Therapeutics, LLC competitors and assessment

Company assessment

Direct peers

  • XGIMI Technology: Chinese premium projector specialist selling 4K home theater and portable projectors (Horizon, AURA series) at comparable price points. XGIMI is the most direct peer in the premium RGB/LED laser consumer projector category with overlapping customer base and similar DLP-based technology stack.
  • JMGO (Shenzhen Holatek): Premium Chinese projector maker offering RGB laser home theater projectors (N1, N1S series) at similar price tiers. Competes head-to-head with Valerion on RGB triple laser technology, Google TV integration, and premium home cinema positioning.
  • BenQ: Established DLP projector brand with strong home theater and gaming projector lines (HT, X, TK series). Targets the same premium home cinema segment with comparable brightness and 4K specifications, and has well-developed retail distribution.
  • Dangbei: Emerging Chinese projector brand (Mars, S7, K3 series) selling premium 4K laser projectors with Google TV. Directly comparable product line, pricing strategy, and target customer segment.
  • Optoma: Dedicated projector specialist with a broad home cinema lineup (CinemaX, UHZ series) at competitive premium price points. Comparable product positioning and distribution strategy in the DLP home theater segment.

Broad incumbents

  • Sony (BRAVIA Projector): Premium incumbent with the BRAVIA Projector line including the VPL-XW7000ES and VPL-GTZ380. Sony is the dominant high-end home theater projector brand and competes in the same ultra-premium tier above Valerion's flagship.
  • LG Electronics (CineBeam): Global consumer electronics incumbent offering CineBeam 4K laser projectors (HU915, HU810) at premium price points. Competes via broader brand reach, retail presence, and integrated webOS smart platform.
  • Hisense (Laser TV): Hisense's Laser TV / Laser Cinema line (L9H, PX3) is among the highest-volume premium RGB laser TV products globally. As a tier-one TV brand, Hisense competes on price-performance and bundled screen offerings.
  • Epson: Established projector incumbent with a full home theater lineup (Pro Cinema, Home Cinema series). While traditionally lamp-based, Epson is moving into laser and competes for the same premium home theater buyer.

Emerging players

  • Anker Nebula: Consumer projector brand under Anker, with portable and home models (Cosmos, Capsule series). Targets adjacent but lower price tiers; relevant as a benchmark for go-to-market scale and brand-building in the consumer projector category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Valerion Therapeutics, LLC social profiles

Digital presence

Valerion Therapeutics, LLC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Valerion Therapeutics, LLC leadership team

Management profile

Number of profiles

Valerion Therapeutics, LLC subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Valerion Therapeutics, LLC funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Valerion Therapeutics, LLC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valerion Therapeutics, LLC

What does Valerion Therapeutics, LLC do?

Valerion Therapeutics, LLC (operating as AWOL Valerion) designs, markets, and sells premium 4K RGB triple laser home theater projectors through its direct-to-consumer e-commerce site at valerion.com. The lineup spans the flagship VisionMaster Max, the gaming-oriented VisionMaster Pro 2 & Pro (Red Dot Award 2025 winner), and the streaming-focused StreamMaster Plus 2 & Plus, complemented by accessory bundles including PureVision Anti-Speckle screens, outdoor and backyard screens, tripod and ceiling mounts, and the Thunderbeat 4.1.2 audio system.

Is Valerion Therapeutics, LLC a public or private company?

Valerion Therapeutics, LLC is a private company. It is classified as unknown and is currently operating.

When was Valerion Therapeutics, LLC founded?

Valerion Therapeutics, LLC was founded in 2007. It employs 1 to 10 people.

Where is Valerion Therapeutics, LLC based?

Valerion Therapeutics, LLC is headquartered in Medford, United States, in the North America region.

How does Valerion Therapeutics, LLC make money?

One revenue line is on record: pre-commercial biopharmaceutical R&D.

Who are Valerion Therapeutics, LLC's main competitors?

Direct peers on record are XGIMI Technology, JMGO (Shenzhen Holatek), BenQ, Dangbei and Optoma. Broad incumbents are Sony (BRAVIA Projector), LG Electronics (CineBeam), Hisense (Laser TV) and Epson. Anker Nebula is listed as an emerging player.

Does Valerion Therapeutics, LLC have an API?

No public API is recorded for Valerion Therapeutics, LLC.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comNano Antibodies Market Overview, Emerging Trends, and Key Player AnalysisThe nano antibodies market is projected to reach $3.79 billion by 2030, growing at a CAGR of 15.9%, driven by demand for precision medicine and increased biologics research investment. In September 2024, France-based Valerion Therapeutics LLC acquired Emglev Therapeutics, a specialist in single-domain antibodies, to strengthen Valerion's capabilities in antibody-based therapeutics and expand into next-generation immunotherapy pipelines. The market report identifies over 20 companies as key players in the nano antibodies space, including Sanofi, AstraZeneca, and Bio-Techne, while also detailing the application of nano antibodies across oncology, infectious diseases, diagnostics, and targeted therapies.PR NewswireValerion to Present Initial Clinical Data with VAL-1221 in Pompe DiseaseValerion Therapeutics announced it will present initial results from the first dosing cohort of its ongoing Phase 1/2 clinical trial with VAL-1221 for late-onset Pompe disease at the WORLDSymposium 2018 in San Diego. VAL-1221 is an investigational fusion protein that uniquely targets both lysosomal and extra-lysosomal glycogen in the cytoplasm, potentially offering improved therapeutic options compared to current enzyme replacement therapies. The international trial is being conducted at Duke University Medical Center and The National Hospital for Neurology and Neurosurgery in London, with enrollment of up to 12 patients previously treated with Myozyme or Lumizyme.PR NewswireValerion Presents Preclinical Proof-of-Concept Data for VAL-0417 for the Treatment of Lafora DiseaseValerion Therapeutics announced preclinical proof-of-concept results for VAL-0417, a novel fusion protein combining its delivery antibody with amylase, as a potential treatment for Lafora disease, a rare and fatal genetic form of epilepsy. The studies, conducted in collaboration with researchers from the University of Kentucky, demonstrated successful delivery of VAL-0417 to skeletal muscle and brain tissue with retention of up to 24 hours following intracerebroventricular injection in Lafora mouse models. The data were presented at the 2017 Lafora Disease Workshop held alongside the 32nd International Epilepsy Congress in Barcelona, Spain.PR NewswireValerion Therapeutics Demonstrates a New Mechanism for Treating Pompe DiseaseValerion Therapeutics announced the development of VAL-1221, a fusion protein combining antibody delivery technology with recombinant human acid alpha-glucosidase for treating Pompe disease, which demonstrated efficacy in clearing both lysosomal and cytoplasmic glycogen in preclinical studies. The therapy showed superior potential over current enzyme replacement therapy by penetrating cells independent of the mannose-6-phosphate receptor mechanism. Valerion is initiating randomized clinical trials at Duke University Medical Center in the US and The National Hospital for Neurology and Neurosurgery in London, UK, with top-line results expected later this year.